-
2
-
-
84946706774
-
Old medications and new targeted therapies in systemic sclerosis
-
Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology 2015; 54: 1944-1953
-
(2015)
Rheumatology
, vol.54
, pp. 1944-1953
-
-
Nagaraja, V.1
Denton, C.P.2
Khanna, D.3
-
3
-
-
84908126065
-
Systemic sclerosis evolution of disease pathomorphosis and survival Our experience on Italian patients' population and review of the literature
-
Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014; 13: 1026-1034
-
(2014)
Autoimmun Rev
, vol.13
, pp. 1026-1034
-
-
Ferri, C.1
Sebastiani, M.2
Lo Monaco, A.3
Iudici, M.4
Giuggioli, D.5
Furini, F.6
-
4
-
-
66149100618
-
EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)
-
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 620-628
-
-
Kowal-Bielecka, O.1
Landewé, R.2
Avouac, J.3
Chwiesko, S.4
Miniati, I.5
Czirjak, L.6
-
5
-
-
33745227399
-
Cyclophosphamide versus placebo in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666
-
(2006)
N Engl J Med
, vol.354
, pp. 2655-2666
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
Goldin, J.4
Roth, M.D.5
Furst, D.E.6
-
6
-
-
33845643063
-
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
-
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970
-
(2006)
Arthritis Rheum
, vol.54
, pp. 3962-3970
-
-
Hoyles, R.K.1
Ellis, R.W.2
Wellsbury, J.3
Lees, B.4
Newlands, P.5
Goh, N.S.6
-
7
-
-
36249001195
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034
-
(2007)
Am J Respir Crit Care Med
, vol.176
, pp. 1026-1034
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
Roth, M.D.4
Furst, D.E.5
Silver, R.M.6
-
8
-
-
77956955777
-
The efficacy of treatment for systemic sclerosis interstitial lung disease: Results from a meta-analysis
-
Broad K, Pope JE. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 2010; 16: RA187-RA190
-
(2010)
Med Sci Monit
, vol.16
, pp. RA187-RA190
-
-
Broad, K.1
Pope, J.E.2
-
9
-
-
55749093240
-
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
-
Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10: R124
-
(2008)
Arthritis Res Ther
, vol.10
, pp. R124
-
-
Nannini, C.1
West, C.P.2
Erwin, P.J.3
Matteson, E.L.4
-
10
-
-
84926335197
-
Systemic sclerosis: A systematic review on therapeutic management from 2011 to 2014
-
Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol 2015; 27: 241-248
-
(2015)
Curr Opin Rheumatol
, vol.27
, pp. 241-248
-
-
Young, A.1
Khanna, D.2
-
11
-
-
84875009952
-
Update on stem cell transplantation for systemic sclerosis: Recent trial results
-
Naraghi K, van Laar JM. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 2013; 15: 326-331
-
(2013)
Curr Rheumatol Rep
, vol.15
, pp. 326-331
-
-
Naraghi, K.1
Van Laar, J.M.2
-
12
-
-
80051468836
-
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial
-
Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506
-
(2011)
Lancet
, vol.378
, pp. 498-506
-
-
Burt, R.K.1
Shah, S.J.2
Dill, K.3
Grant, T.4
Gheorghiade, M.5
Schroeder, J.6
-
13
-
-
84902844800
-
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial
-
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498
-
(2014)
JAMA
, vol.311
, pp. 2490-2498
-
-
Van Laar, J.M.1
Farge, D.2
Sont, J.K.3
Naraghi, K.4
Marjanovic, Z.5
Larghero, J.6
-
15
-
-
0018887574
-
Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee preliminary criteria for the classification of systemic sclerosis (scleroderma)
-
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590
-
(1980)
Arthritis Rheum
, vol.23
, pp. 581-590
-
-
-
16
-
-
84886777196
-
2013 classification criteria for systemic sclerosis: An American College of Rheumatology/ European League against Rheumatism collaborative initiative
-
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/ European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747
-
(2013)
Arthritis Rheum
, vol.65
, pp. 2737-2747
-
-
Vanden Hoogen, F.1
Khanna, D.2
Fransen, J.3
Johnson, S.R.4
Baron, M.5
Tyndall6
-
17
-
-
0027729083
-
Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies
-
Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896
-
(1993)
J Rheumatol
, vol.20
, pp. 1892-1896
-
-
Clements, P.J.1
Lachenbruch, P.A.2
Seibold, J.R.3
Zee, B.4
Steen, V.D.5
Brennan, P.6
-
18
-
-
0042508746
-
European scleroderma study group to define disease activity criteria for systemic sclerosis III assessment of the construct validity of the preliminary activity criteria
-
Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901-903
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 901-903
-
-
Valentini, G.1
Bencivelli, W.2
Bombardieri, S.3
D'Angelo, S.4
Della Rossa, A.5
Silman, A.J.6
-
19
-
-
0038799774
-
Natural history of systemic sclerosis and the assessment of severity, functional state, and phychologic well-being
-
Medsger TA. Natural history of systemic sclerosis and the assessment of severity, functional state, and phychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-273
-
(2003)
Rheum Dis Clin North Am
, vol.29
, pp. 255-273
-
-
Medsger, T.A.1
-
20
-
-
84949292966
-
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?
-
Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant 2016; 51: 501-505
-
(2016)
Bone Marrow Transplant
, vol.51
, pp. 501-505
-
-
Oliveira, M.C.1
Labopin, M.2
Henes, J.3
Moore, J.4
Papa, N.D.5
Cras6
-
21
-
-
78650663333
-
Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma
-
Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70: 104-109
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 104-109
-
-
Domsic, R.T.1
Rodriguez-Reyna, T.2
Lucas, M.3
Fertig, N.4
Medsger, T.A.5
-
22
-
-
84932632017
-
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
-
Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124-1131
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 1124-1131
-
-
Maurer, B.1
Graf, N.2
Michel, B.A.3
Müller-Ladner, U.4
Czirják, L.5
Denton, C.P.6
-
23
-
-
84875725309
-
Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: A retrospective analysis
-
Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116-1124
-
(2013)
Lancet
, vol.381
, pp. 1116-1124
-
-
Burt, R.K.1
Oliveira, M.C.2
Shah, S.J.3
Moraes, D.A.4
Simoes, B.5
Gheorghiade, M.6
-
24
-
-
84983134063
-
Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis
-
van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology 2015; 54: 2126-2133
-
(2015)
Rheumatology
, vol.54
, pp. 2126-2133
-
-
Van Laar, J.M.1
Naraghi, K.2
Tyndall, A.3
|